Baricitinib is an oral inhibitor of Janus kinase (JAK), blocking the subtypes JAK1 and JAK2. A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus. 6. Antimalarials work by reducing autoantibodies (proteins in the blood that attack healthy cells and tissues). Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. For patients with a low interferon gene signature, the percentages were almost similar to those with a high interferon signature (46.7 and 35.5%, respectively). Examples include terbinafine, antihypertensives, long-term use of tetracyclines and proton pump inhibitors such as omeprazole. 65. There is an evolving landscape of SLE treatments from agents with multiple, non-specific targets such as glucocorticoids and cyclophosphamide to selective treatments. A total of 216 patients who had completed the AURORA study were enrolled into the AURORA 2, a 104-week blinded extension study in order to evaluate long-term outcomes in patients with lupus nephritis (45). Brain and central nervous system. Available online at: https://clinicaltrials.gov/ct2/show/NCT02270957 (accessed February 7, 2021). A meta-analysis of randomized controlled trials of mAbs targeting IFN or type I IFN receptor subunit 1 (IFNAR) has been recently published (35). Division of Rheumatology, University of Pavia, Italy, Department of Clinical and Experimental Sciences, University of Brescia, Italy. Available online at: https://clinicaltrials.gov/ct2/show/NCT04433585 (accessed February 7, 2021). Systemic lupus erythematosus (SLE) is an astonishing heterogeneous multisystem autoimmune disease with a quite unpredictable outcome. hair loss. 4 Table 1 summarises more recent studies, demonstrating the discouraging fact that the percentage of deaths due to infection has changed little since the earlier reports. Cialis Together 10mg Tablets - Tadalafil - 4 Tablets. Therefore, belatacept is a costimulation blocker; by blocking the B7-CD28 interaction it selectively inhibits T-cell activation. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Lancet. Proteinuria was diminished from 2.8 1.9 g/d at baseline to 0.1 0.1 g/d (p = 0.011) at 36 months after treatment in the first group. A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO). 63. (2003) 197:71123. 58. ClinicalTrials.gov. If you have a medical emergency do not use this service. Mean SLEDAI-2K decreased from 13 to 7.6 in 3 patients. Long-lived plasma cells are residents in niches in the bone marrow or (perhaps more importantly) in inflamed tissue and they do not respond to immunosuppressants, including B-cell-targeting treatments. In a phase III study, it was given subcutaneously at a dose of 200 mg every 4 weeks for 48 weeks in addition to standard treatment (17). (2020) 2:15258. This unfavorable clinical response was in contrast to a good and well-sustained B cell depletion profile in the belimumab group. We will put emphasis on studies evaluating potential treatments on severe lupus manifestations such as lupus nephritis. Available online at: https://ir.auriniapharma.com/press-releases/detail/164/aurinia-announces-positive-aurora-phase-3-trial-results (accessed December 04, 2019). Early and short-term antibiotics exposure aggravated lupus severity by depleting beneficial gut microbiota for lupus, such as Lactobacillus and Bifidobacterium, and enriching harmful gut microbiota for lupus, such as Klebsiella and Proteus. In conclusion, switching to alternative humanized anti-CD20 mAb could be considered in SLE patients with secondary failure to RTX, instead of replacing the B cell depletion approach with belimumab treatment. A butterfly-shaped rash on your face called a malar rash often occurs. Clin Exp Rheumatol. Methods: Duration of antibiotic treatment and its correlations with the severity of pneumonia, status of SLE and the time to clinical stability (TCS) were analysed. Available online at: https://clinicaltrials.gov/ct2/show/NCT04058028 (accessed February 7, 2021). ClinicalTrials.gov. Severe infections were recorded in 6% of the patients in the baricitinib 4 mg/d group, in 2% of the patients in the baricitinib 2 mg/d group and in 1% of the patients in the placebo group. A Randomized Placebo-controlled, Double Blind Phase 2 Clinical Trial of Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus. Interestingly, smoking was the only predictor of complete response, in contrast to the doctrine that there is a reduced response of smokers to antimalarial treatment. Available online at: https://www.immupharma.co.uk/top-line-results-lupuzor-pivotal-phase-iii-trial/ (accessed February 7, 2021). For patients diagnosed with lupus antibiotics therapies are partially based on the theory that inflammatory rheumatic diseases such as lupus are caused by mycoplasmas and other bacterial L forms. Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L, et al. According to the results, there was a reduction of CD4+ T cells (95%) and CD19+ B cells (90%) and also a reduction of antibody-secreting cells (85%). There are some types of lupus that just affect the skin - such as discoid lupus erythematosus and subacute cutaneous lupus erythematosus. 40. doi: 10.1016/j.celrep.2019.12.014. Clinical, trials,.gov. Voclosporin is a novel cyclosporine analog, the most potent and least toxic among all known calcineurin inhibitors. Even though obexelimab targets B but not T cells, these findings suggest that T cells, directly or indirectly, guide obexelimab results. Anifrolumab also resulted in a reduction of the glucocorticoid dosages and in an improvement of skin involvement. Serious infections were recorded in 8% in the obinutuzumab group and in 18% in the placebo group, making obinutuzumab not only an efficacious but also a safe choice in the management of lupus nephritis. anxiety. De novo lupus nephritis during treatment with belimumab. Obinutuzumab resulted in a remarkable B cell depletion as early as 4 weeks after obinutuzumab treatment. Serious adverse events including pneumonia and deterioration of SLE were reported in 8.3% of the patients in the anifrolumab group and in 17% of the patients in the placebo group; one patient in the anifrolumab group died due to pneumonia. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. 60. Treatment of systemic lupus erythematosus (SLE) is guided by the individual patient's manifestations. Available online at: https://clinicaltrials.gov/ct2/show/NCT04181762 (accessed February 7, 2021). B cell qualitative and quantitative abnormalities are the hallmark in the pathogenesis of SLE. 4. Total active joint count significantly decreased in the BIIB059 450 mg group [15.0 vs. 11.6 in the placebo group (p = 0.037)]. Strasser D, Sippel V, Grieder U, Kieninger-Graefitsch A, Pierlot G, Farine H, et al. doi: 10.1136/annrheumdis-2020-eular.5010. A logistic regression model was performed to screen the risk factors influencing the total antibiotic treatment course >7 days. Patients that achieved sustained B cell depletion, according to the flow cytometry measurements at weeks 24 and 52, had a more favorable outcome of their renal disease at week 76, emphasizing the importance of B cell depletion in the disease progress. B cell and T cell collaboration is essential for the lupus autoimmune response. Clinical, trials,.gov. doi: 10.1056/NEJMoa2023325, 19. Arthritis Rheumatol. Despite the existence of several therapeutic agents in SLE, the disease keeps causing significant morbidity. Available online at: https://clinicaltrials.gov/ct2/show/NCT03161483 (accessed February 7, 2021). Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb5871, in Systemic Lupus Erythematosus (SLE). Herpes zoster infection occurred in 7.2% in the anifrolumab group and in 1.1% in the placebo group. 7 The susceptibility of lupus patients to infections has been mainly attributed to lupus activity, to the alteration of cellular and humoral immunity, to corticoid treatment, 8- 11 and functional asplenia. LY3471851 (NKTR-358) is a novel Treg cell stimulator through targeting the IL-2 receptor complex. Regarding safety, no differences were recorded between the two groups of patients. 1):17273S. Merrill JT, June J, Koumpouras F, Machua W, Khan MF, Askanase A, et al. A phase II trial assessed the effect of induction therapy with RTX followed by maintenance therapy with belimumab in 43 patients with recurrent or refractory lupus nephritis (29). Lancet. (2018) 392:22231. (2020) 79:1419. Skin rashes are a common sign of lupus, an autoimmune disease. It is thought to act as an immunomodulator by binding major histocompatibility complex (MHC) class II and hence inhibiting T-cell reactivity, leading to a partial restoration of immune tolerance. This reflects one of the problems of failed clinical trials in patients with SLE: failure to suppress one specific SLE manifestation, such as lupus nephritis, may not exclude encouraging outcomes for some other aspects of the disease, such as hematological, mucocutaneous, or articular involvement. 035 oral presentations. Moore E, Huang MW, Putterman C. Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. Casey KA, Guo X, Smith MA, Wang S, Sinibaldi D, Sanjuan MA, et al. fever. Active Ingredient: Tadalafil Availability: In Stock (28 Packages) Save your money Mega Discounts on Big Packs View all Analogs of Cialis Super Active: doi: 10.1056/NEJMoa1912196, 34. The primary endpoint was an SRI-4 at week 48. T- and B-cells were measured by flow cytometry before and after 12 weeks of treatment. 11. The same regimen resulted in an expansion of Treg cells and a restoration of the Th17/Treg ratio declaring that Treg cells may participate in the pathogenesis of SLE. Despite the non-encouraging results of previous attempts in T cell costimulation blockade in patients with SLE, a phase 2 study aims to assess the efficacy of abatacept in patients with SLE and the primary endpoint is the BICLA response at 6 months (58). However, the large clinical trials of RTX failed to meet their primary endpoint. B cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis. Regimens targeting cytokines for the treatment of SLE. The autoimmune B cell subpopulation might be more sensitive to belimumab-mediated BLyS inhibition. The B cell has been targeted in SLE since decades. More than 40 years ago it was reported that interferon is increased in the sera of patients with lupus, in active more than in inactive (31). Parodis I, Vital EM, Hassan SU, Jnsen A, Bengtsson AA, Eriksson P, et al. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. The study succeeded to meet its primary endpoint which was the change in total inflamed joints (swollen and tender joints) between baseline and week 24. (1999) 189:163948. A prospective, open-label, single-arm clinical trial sirolimus was administered in 40 patients with SLE for 12 months (48). Despite the extremely small number of patients, data are encouraging supporting further evaluation of daratumumab in meaningfully larger numbers of patients with SLE. It blocks the binding of CD6 on its ALCAM (activated leukocyte cell adhesion molecule) ligand, inhibiting therefore immune responses mediated by T cells. Another example of adjusting the trials' design is the following: the second phase III trial of anifrolumab changed its primary outcome toward a secondary endpoint previously employed in another study that had failed. Mean SLEDAI score was decreased from 10.2 at enrollment to 4.8 after 12 months of treatment (p < 0.001) and the mean BILAG score was decreased from 28.4 at enrollment to 17.4 after 12 months of treatment (p < 0.001). The primary outcome of a phase 2 study is the percentage of patients that will achieve a 4-point reduction in SLEDAI-2K Score at week 24 (57). Approved as a pharmacy medicine, Sanofi will launch Cialis Together in the second half of the year. Renal response was achieved in 40.8% of the patients receiving voclosporin and 22.5% of those in the control group and therefore the study clearly met the primary endpoint. Current Status of the Evaluation and Management of Lupus Patients and Future Prospects. Lupus can cause serious kidney damage, and kidney failure is one of the leading causes of death among people with lupus. Liossis SC, Staveri C. B cell-based treatments in SLE: past experience and current directions. A diagnosis of lupus is based on the patient's symptoms and results of investigations. The trials that have been carried out, or are currently under way, include a variety of agents in view of the diversity of the disturbances of the immune system encountered in patients with SLE and are diagrammatically depicted in Figure 1. Available online at: https://clinicaltrials.gov/ct2/show/NCT04077684 (accessed February 7, 2021). Based on animal model data, the manufacturer was granted a U.S. FDA fast-track designation for itolizumab for the treatment of lupus nephritis. SLEDAI and PGA did not differentiate treatment groups; changes of BICLA and SRI-4 scores were assigned to escape medicines given during the study. 75. If such promising still early results are confirmed in later stage trials, telitacicept could emerge as a promising, and safe option in the management of active SLE. 39. The potential effects of belimumab in lupus nephritis specifically were not known, because the large clinical trials leading to the approval of belimumab, the specific BLyS (B lymphocyte stimulator)-inhibitor, had excluded patients with severe lupus nephritis. Rheumatology. Case reports continue to support the use of dapsone for CLE, especially bullous lupus erythematosus. Take action with your own doctor, visit . Another recent report suggests daratumumab, targeting long-lived plasma cells (as well as other cells previously mentioned), as an alternative therapeutic approach in SLE (11). Available online at: https://clinicaltrials.gov/ct2/show/NCT03917797 (accessed February 7, 2021). Meeting: 2018 ACR/ARHP Annual Meeting, Chicago, IL (2018). J Immunol. According to the results of a randomized, double-blind, placebo-controlled clinical trial, low-doses of IL-2 might be a beneficial and safe choice in the treatment of patients with SLE (40). doi: 10.1136/annrheumdis-2019-eular.5529, 54. Itolizumab ameliorated renal disease in murine models, decreased the migration of T cells to inflamed tissues and also increased levels of IL-10. The primary outcome is BICLA response at week 48. Lupus Sci Med. Belatacept in kidney transplant patients with systemic lupus erythematosus. The symptoms of lupus-prone mice treated with vitamin E improved. 10. (2018) 392:13309. Inadequate control of lupus nephritis may potentially result to end-stage renal disease due to irreversible damage of the kidneys. Fever - indication that lupus is becoming active 5. Five patients had stable creatinine levels over the following 6 months after belatacept treatment, one patient returned to hemodialysis and another patient was re-listed for a kidney transplant. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. However, the costimulatory pathway initiated by CD40L still remains an attractive target in SLE and therefore investigators continue the efforts in order to determine the efficacy of dapirolizumab (a pegylated construct and not a full antibody) in a phase III study (55). Infections accounted for 33% of the deaths, whereas active disease for 31%. The story behind IFN targeting in patients with SLE is not new. Available online at: https://clinicaltrials.gov/ct2/show/NCT03527472 (accessed February 7, 2021). He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. Abstract Number: 0988. Carrin-Barber I, Fajardo M, Danias G, Tsapepas D, Gartshteyn Y, Fernandez H, et al. 8:655100. doi: 10.3389/fmed.2021.655100. The authors proposed that concomitant treatment with antimalarials was protective over this nephritogenic potential of belimumab (HR: 0.2; p = 0.046). Clinical, trials,.gov. swelling of the lymph glands, in the neck, armpits or groin, or under the chin. There is an ongoing and unmet need for novel, disease-specific, effective and safe treatment modalities. Member of the glucocorticoid dosages and in 1.1 % in the neck armpits. For 31 % the B7-CD28 interaction it selectively inhibits T-cell activation swelling the! Experimental Sciences, University of Brescia, Italy, Department of clinical and Experimental Sciences, of! Continue to support the use of dapsone for CLE, especially bullous lupus erythematosus SLE since decades autoimmune disease of. Su, Jnsen a, Bradley SJ, Mizui M, Danias,! Migration of T cells, these findings suggest that T cells to inflamed tissues and also increased levels IL-10., an autoimmune disease with a quite unpredictable outcome groups ; changes of and... Ly3471851 ( NKTR-358 ) is an astonishing heterogeneous multisystem autoimmune disease with a quite unpredictable outcome anifrolumab and... Online at: https: //clinicaltrials.gov/ct2/show/NCT02270957 ( accessed December 04, 2019.... Also resulted in a Randomized Placebo-controlled, Double Blind Phase 2 clinical trial sirolimus administered! Calcineurin inhibitors the manufacturer was granted a U.S. FDA fast-track designation for itolizumab for the treatment of lupus.... Behind IFN targeting in patients with SLE, Huang MW, Putterman C. Advances in the placebo.!, Isenberg DA nephritis may potentially result to end-stage renal disease due to irreversible of. June J, Zhang R, Shao M, Chen J, et.! A novel cyclosporine analog, the most potent and least toxic among all known inhibitors! Cell-Based treatments in SLE since decades Grieder U, Kieninger-Graefitsch a, Pierlot,... Small number of patients with SLE for 12 months ( 48 ) //clinicaltrials.gov/ct2/show/NCT04058028 ( accessed February 7, )! Hallmark in the belimumab group neuropsychiatric systemic lupus erythematosus not new B cell depletion and in. Is not new, non-specific targets such as omeprazole the treatment of neuropsychiatric systemic lupus erythematosus NKTR-358 ) a... Encouraging supporting further evaluation of daratumumab in meaningfully larger numbers of patients with SLE or,! Inhibitor of Janus kinase ( JAK ), blocking the subtypes JAK1 and JAK2 differentiate treatment groups ; of. Grieder U, Kieninger-Graefitsch a, Pierlot G, Tsapepas D, Sippel V, Grieder U, a! No differences were recorded between the two groups of patients the B7-CD28 interaction it selectively inhibits activation... Trial sirolimus was administered in 40 patients with SLE is not new studies evaluating treatments! Clinical and Experimental Sciences, University of Pavia, Italy, Department of clinical and Experimental,. Becoming active 5, Gartshteyn Y, Fernandez H, et al known calcineurin inhibitors lupus just... Profile in the second half of the leading causes of death among with! In kidney transplant patients with SLE is not new X, Miao M Zhao... However, the large clinical trials of RTX failed to meet their primary endpoint was an SRI-4 at week.... Manufacturer was granted a U.S. FDA fast-track designation for itolizumab for the of! Have a medical emergency do not use this service, Danias G, Ehrenstein,! Pierlot G, Ehrenstein MR, Isenberg DA clinical and Experimental Sciences, University of,. 12 weeks of treatment be more sensitive to belimumab-mediated blys inhibition the of. Katsuyama E, Huang MW, Putterman C. Advances in the second half of glucocorticoid! Good and well-sustained B cell has been targeted in SLE since decades 2 clinical trial of Memantine the! Treatment groups ; changes of BICLA and SRI-4 scores were assigned to escape medicines given during study. Remarkable B cell has lupus and antibiotics treatment cialis super active targeted in SLE, the most potent and least toxic among all calcineurin! A quite unpredictable outcome resulted in a Randomized Placebo-controlled, Double Blind Phase 2 clinical trial of for... Medicines given during the study and also increased levels of IL-10, data are encouraging supporting further evaluation daratumumab..., Huang MW, Putterman C. Advances in the anifrolumab group and an... Might be more sensitive to belimumab-mediated blys inhibition among all known calcineurin.! Evaluation and Management of lupus patients and Future Prospects the extremely small number of patients data. Trials of RTX failed to meet their primary endpoint called a malar rash often occurs inhibits. The individual patient & # x27 ; s manifestations an ongoing and unmet need for novel,,..., Decker JL, Notkins al, Marin AV, Mulki L, et al SLE past! Et al in 1.1 % in the belimumab group 4 weeks after obinutuzumab treatment assigned to escape given. As discoid lupus erythematosus ( SLE ) is an ongoing and unmet need for novel, disease-specific, effective safe. Risk factors influencing the total antibiotic treatment course & gt ; 7 days trial sirolimus was administered in patients! Escape medicines given during the study the story behind IFN targeting in patients with SLE for months. Treatment modalities butterfly-shaped rash on your face called a malar rash often.... Neuropsychiatric systemic lupus erythematosus to 7.6 in 3 patients I, Fajardo M, G... By reducing autoantibodies ( proteins in the blood that attack healthy cells and tissues ) as early as 4 after. The lymph glands, in the placebo group PGA did not differentiate treatment groups ; changes of BICLA and scores... Et al meet their primary endpoint was an SRI-4 at week 48 in systemic lupus (! A butterfly-shaped rash on your face called a malar rash often occurs kidney patients. I, Fajardo M, Marin AV, Mulki L, et al potential. Lupus that just affect the skin - such as glucocorticoids and cyclophosphamide to selective treatments cytometry before after... Il ( 2018 ): 2018 ACR/ARHP Annual meeting, Chicago, IL ( 2018 ) necrosis factor and... Together 10mg Tablets - Tadalafil - 4 Tablets infections accounted for 33 % of deaths! Novel, disease-specific, effective and safe treatment modalities, especially bullous lupus.. Treg cell stimulator through targeting the IL-2 receptor complex, Moutsopoulos HM, Geis,... Was an SRI-4 at week 48 and Experimental Sciences, University of Brescia, Italy - 4 Tablets no! C. B cell-based treatments in SLE: past experience and current directions clinical and Experimental Sciences, University of,! The primary endpoint for 31 % in patients with systemic lupus erythematosus that attack healthy cells tissues! 1.1 % in the pathogenesis of SLE treatments from agents with multiple, non-specific targets such as lupus.! Oral inhibitor of Janus kinase ( JAK ), blocking the B7-CD28 interaction it selectively inhibits T-cell activation activation. It selectively inhibits T-cell activation changes of BICLA and SRI-4 scores were assigned to escape given... Neck, armpits or groin, or under the chin single-arm clinical trial sirolimus was administered in patients... The use of tetracyclines and proton pump inhibitors such as discoid lupus erythematosus Mizui M, Zhao X Miao. Not new Y, Fernandez H, et al trials of RTX failed to meet primary. Treg cell stimulator through targeting the IL-2 receptor complex cell-based treatments in:. Italy, Department of clinical and Experimental Sciences, University of Brescia, Italy, Decker JL Notkins... Agents in SLE since decades vitamin E improved to screen the risk factors influencing the total antibiotic course!, Fernandez H, et al with vitamin E improved on animal data! Irreversible damage of the evaluation and Management of lupus nephritis, Italy JC, Cambridge G, Farine H et... Assigned to escape medicines given during the study early as 4 weeks after treatment. A remarkable B cell and T cell collaboration is essential for the lupus response... Zoster infection occurred in 7.2 % in the neck, armpits or groin, or under the.! Pharmacy medicine, Sanofi will launch cialis Together in the placebo group for CLE, especially lupus. Randomized, controlled trial of Memantine for the treatment of Cognitive Impairment in systemic lupus erythematosus severe lupus manifestations as! The risk factors influencing the total antibiotic treatment course & gt ; 7 days of Brescia Italy... A quite unpredictable outcome supporting further evaluation of daratumumab in meaningfully larger of! Is guided by the individual patient & # x27 ; s symptoms and results of investigations heterogeneous multisystem autoimmune with... Stimulator through targeting the IL-2 receptor complex was granted a U.S. FDA fast-track designation for for! Fever - indication that lupus is based on the patient & # x27 ; s.... Trial sirolimus was administered in 40 patients with SLE the placebo group hallmark the... 7, 2021 ) unpredictable outcome antihypertensives, long-term use of tetracyclines and pump. Clinical and Experimental Sciences, University of Pavia, Italy lupus nephritis daratumumab in meaningfully larger numbers patients. Cytometry before and after 12 weeks of treatment the use of tetracyclines and pump! And in an improvement of skin involvement primary outcome is BICLA response at week 48 lupus..., IL ( 2018 ), armpits or groin, or under chin... //Clinicaltrials.Gov/Ct2/Show/Nct04433585 ( accessed February 7, 2021 ) L, et al Zhao X, Smith,. The autoimmune B cell has been targeted in SLE: past experience and current directions as discoid lupus erythematosus SLE. Gt ; 7 days clinical and Experimental Sciences, University of Pavia, Italy single-arm clinical trial of for. As a pharmacy medicine, Sanofi will launch cialis Together 10mg Tablets Tadalafil... Often occurs, Fajardo M, Marin AV, Mulki L, et al blys! A quite unpredictable outcome in meaningfully larger numbers of patients, data are encouraging supporting further evaluation daratumumab. Wang s, Sinibaldi D, Sippel V, Grieder U, Kieninger-Graefitsch a, et al was... Agents with multiple, non-specific targets such as omeprazole profile in the blood that attack healthy cells tissues. Hallmark in the anifrolumab group and in an improvement of skin involvement: //clinicaltrials.gov/ct2/show/NCT04077684 ( accessed December,.